Cargando…
Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
BACKGROUND/PURPOSE: Age-related macular degeneration (AMD) is the leading cause of visual impairment in patients over 55 years. Currently, the most common therapies for neovascular AMD (nAMD) are intravitreal antiangiogenics. Studies suggest that genetic factors influence on antiangiogenics therapy...
Autores principales: | Rodríguez, Francisco Jose, Rios, Hernan Andres, Aguilar, María Camila, Rosenstiehl, Shirley Margarita, Gelvez, Nancy, Lopez, Greizy, Tamayo, Martha L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947742/ https://www.ncbi.nlm.nih.gov/pubmed/31942429 http://dx.doi.org/10.4103/tjo.tjo_72_19 |
Ejemplares similares
-
Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
por: Sabour-Pickett, Sarah, et al.
Publicado: (2013) -
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021) -
Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Matsumiya, Wataru, et al.
Publicado: (2011)